Literature DB >> 3933718

Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case-control study.

A Muuronen, M Kaste, E A Nikkilä, E M Tolppanen.   

Abstract

Patients who use phenytoin and some other anticonvulsive drugs have been shown to have raised concentrations of plasma high density lipoprotein. As this lipoprotein is known to be inversely associated with the incidence of ischaemic heart disease the causes of death of all patients with epilepsy known to be taking anticonvulsive drugs who died during 1978-80 were studied. Of 1399 deaths of anticonvulsant users, 258 (18.4%) were caused by ischaemic heart disease. This was significantly less (p less than 0.001) than the 382 deaths from ischaemic heart disease (27.3%) observed among paired controls matched for sex, age, and date of death. The total cardiovascular mortality was also lower among patients with epilepsy than among controls (p less than 0.02) despite there being more deaths due to cerebrovascular disease among patients. The difference in mortality from ischaemic heart disease was significant for both sexes and was not accounted for by excess deaths due to any other single cause. Users of phenytoin, carbamazepine, and barbiturates (alone or in combination) showed 29% less mortality due to ischaemic heart disease than respective controls (p less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3933718      PMCID: PMC1418106          DOI: 10.1136/bmj.291.6507.1481

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  14 in total

1.  Letter: Phenytoin and serum cholesterol.

Authors:  S Livingston
Journal:  Br Med J       Date:  1976-03-06

2.  Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland.

Authors:  K Pyöräla
Journal:  Diabetes Care       Date:  1979 Mar-Apr       Impact factor: 19.112

3.  Serum elevation of high density lipoprotein (HDL) cholesterol in epileptic patients taking carbamazepine or phenytoin.

Authors:  B O'Neill; N Callaghan; M Stapleton; W Molloy
Journal:  Acta Neurol Scand       Date:  1982-02       Impact factor: 3.209

Review 4.  High density lipoproteins and atherosclerosis.

Authors:  G J Miller
Journal:  Annu Rev Med       Date:  1980       Impact factor: 13.739

5.  Mortality in patients with epilepsy.

Authors:  W A Hauser; J F Annegers; L R Elveback
Journal:  Epilepsia       Date:  1980-08       Impact factor: 5.864

6.  Serum lipids and anticonvulsants.

Authors:  P Berlit; K H Krause; C C Heuck; B Schellenberg
Journal:  Acta Neurol Scand       Date:  1982-09       Impact factor: 3.209

7.  Effect of diphenylhydantoin on insulin secretion in man.

Authors:  C Malherbe; K C Burrill; S R Levin; J H Karam; P H Forsham
Journal:  N Engl J Med       Date:  1972-02-17       Impact factor: 91.245

8.  Effect of phenobarbitone on plasma apolipoprotein B and plasma high-density-lipoprotein cholesterol in normal subjects.

Authors:  P N Durrington
Journal:  Clin Sci (Lond)       Date:  1979-05       Impact factor: 6.124

9.  Ischemic heart disease in patients with epilepsy.

Authors:  J F Annegers; L R Elveback; D R Labarthe; W A Hauser
Journal:  Epilepsia       Date:  1976-03       Impact factor: 5.864

10.  Heart disease mortality and morbidity in patients with epilepsy.

Authors:  J F Annegers; W A Hauser; S B Shirts
Journal:  Epilepsia       Date:  1984-12       Impact factor: 5.864

View more
  7 in total

1.  High-density lipoprotein subfractions, apolipoproteins and antipyrine clearance in normal subjects.

Authors:  P V Luoma; A Rautio; J Stengård; E A Sotaniemi; J Marniemi
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Antipyrine and metronidazole metabolism during occupational exposure to gasoline.

Authors:  M Døssing; S Loft; J Sonne; E Schroeder
Journal:  Int Arch Occup Environ Health       Date:  1988       Impact factor: 3.015

Review 3.  Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels.

Authors:  A K Mantel-Teeuwisse; J M Kloosterman; A H Maitland-van der Zee; O H Klungel; A J Porsius; A de Boer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Atherogenic consequence of antiepileptic drugs: a study of intima-media thickness.

Authors:  Masoud Mehrpour; Mahsa Shojaie; Babak Zamani; Safoora Gharibzadeh; Mehrshad Abbasi
Journal:  Neurol Sci       Date:  2013-07-13       Impact factor: 3.307

5.  Antiepileptic drugs and markers of vascular risk.

Authors:  Carla Lopinto-Khoury; Scott Mintzer
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

Review 6.  Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations.

Authors:  James W McAuley; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Cytochrome P450 and gene activation--from pharmacology to cholesterol elimination and regression of atherosclerosis.

Authors:  Pauli V Luoma
Journal:  Eur J Clin Pharmacol       Date:  2008-07-17       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.